First-in-human controlled inhalation of thin graphene oxide nanosheets to study acute cardiorespiratory responses
Andrews, Jack P.M. (The Royal Infirmary of Edinburgh)
Joshi, Shruti S. (University of Edinburgh)
Tzolos, Evangelos (University of Edinburgh)
Syed, Maaz B. (University of Edinburgh)
Cuthbert, Hayley (The Royal Infirmary of Edinburgh)
Crica, Livia E. (The University of Manchester)
Lozano, Neus (Institut Català de Nanociència i Nanotecnologia)
Okwelogu, Emmanuel (The University of Manchester)
Raftis, Jennifer B. (University of Edinburgh)
Bruce, Lorraine (University of Edinburgh)
Poland, Craig A. (University of Edinburgh)
Duffin, Rodger (University of Edinburgh)
Fokkens, Paul H.B. (National Institute for Public Health and the Environment)
Boere, A. John F. (National Institute for Public Health and the Environment)
Leseman, Daan L.A.C. (National Institute for Public Health and the Environment)
Megson, Ian L. (University of the Highlands and Islands)
Whitfield, Phil D. (University of the Highlands and Islands)
Ziegler, Kerstin (University of the Highlands and Islands)
Tammireddy, Seshu (University of the Highlands and Islands)
Hadjidemetriou, Marilena (The University of Manchester)
Bussy, Cyrill (The University of Manchester)
Cassee, Flemming R. (Utrecht University)
Newby, David E. (University of Edinburgh)
Kostarelos, Kostas (Institut Català de Nanociència i Nanotecnologia)
Miller, Mark R. (University of Edinburgh)

Date:	2024
Abstract:	Graphene oxide nanomaterials are being developed for wide-ranging applications but are associated with potential safety concerns for human health. We conducted a double-blind randomized controlled study to determine how the inhalation of graphene oxide nanosheets affects acute pulmonary and cardiovascular function. Small and ultrasmall graphene oxide nanosheets at a concentration of 200 μg m or filtered air were inhaled for 2 h by 14 young healthy volunteers in repeated visits. Overall, graphene oxide nanosheet exposure was well tolerated with no adverse effects. Heart rate, blood pressure, lung function and inflammatory markers were unaffected irrespective of graphene oxide particle size. Highly enriched blood proteomics analysis revealed very few differential plasma proteins and thrombus formation was mildly increased in an ex vivo model of arterial injury. Overall, acute inhalation of highly purified and thin nanometre-sized graphene oxide nanosheets was not associated with overt detrimental effects in healthy humans. These findings demonstrate the feasibility of carefully controlled human exposures at a clinical setting for risk assessment of graphene oxide, and lay the foundations for investigating the effects of other two-dimensional nanomaterials in humans. Clinicaltrials. gov ref: NCT03659864.
Grants:	Agencia Estatal de Investigación CEX2021-001214-S Agencia Estatal de Investigación SEV-2017-0706
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Published in:	Nature Nanotechnology, Vol. 19 (February 2024) , p. 705-714, ISSN 1748-3395

DOI: 10.1038/s41565-023-01572-3
PMID: 38366225

25 p, 4.4 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Experimental sciences > Catalan Institute of Nanoscience and Nanotechnology (ICN2)
Articles > Research articles
Articles > Published articles